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Can the ECNP medicines chest save them?Introduction
There is great concern amongst ecologists and the general
public over the loss of species particularly in the animal
kingdom. For the past 30 or more years we have seen a
similar phenomenon in pharmacological science – the loss of
important compounds that are vital to research particularly
in the clinical ﬁeld. It is now time to acknowledge the scale
and signiﬁcance of this problem. In an effort to remedy this
problem, the ECNP are trying to facilitate access for
researchers to pharmacological tools in order to support
experimental medicine studies through the Medicines Chest
initiative. Targeted compounds for inclusion in the Medi-
cines Chest are those that have selective actions at
important brain targets, and could readily be employed in
human studies, for example, compounds that have been
shelved by Pharmaceutical companies but for which clinical
safety packages and possibly active pharmaceutical ingre-
dients are available.1. The drug discovery and disappearance
process
Most drug discovery and clinical development is done by the
pharmaceutical industry. This is for reasons of time and
cost. It takes over a decade and up to a billion dollars to get
a drug on the market, and few non-commercial or charity
funders have access to this level of resource. At many points
in this process “failure” can occur and the drug is then
shelved, often with no further exploration of other possible
therapeutic indications. Such drugs then disappear from the
company's consciousness, and then from the archives, so
that they may never be seen or heard of again. This loss of
access to useful research tools and the accrued knowledge is
vast and spreads across all areas of drug discovery and
development. This is a contributory reason to why so many
new drugs fail to make the transition to successful clinical
treatments. Preclinical pharmacology models readily deliver
new targets for drug discovery, but the translation to human
psychiatric illness is poor. A major reason for this is that tool
compounds are not available for human research.lsevier B.V. and ECNP.
0.1016/j.euroneuro.2014.01.018
Open access under CC BY-NCAlthough the published data on the compound is in the
public domain, a lot of important data covering the safety
proﬁle and manufacturing is never published. Moreover
although some compounds are made available to preclinical
researchers via chemical supply companies, clinical research
is almost invariably impossible so a whole clinical research
ﬁeld can suddenly terminate. Following are two examples
from brain research, the area of interest to the ECNP
Medicines Chest initiative, though similar issues can be found
in other treatment areas.
Noradrenaline is a long-established brain neurotransmit-
ter that animal studies indicate is involved in the regulation
of attention and arousal and may be abnormal in conditions
such as depression, drug addiction and dementias (Brunello
et al., 2002; Sofuoglu and Sewell, 2009; Herrmann et al.,
2004). Brain noradrenaline works through several sub-
types of receptors – the alphas [1,2] and the betas [1,2,3].
In order to fully understand this system in human brain
function and disease it is necessary to have access to drugs
that selectively target each receptor subtype. In the 1980s
several companies developed compounds that acted as
antagonists of the α2 receptor because blocking this recep-
tor takes off the pre-synaptic break on noradrenaline
release, thus enhancing its actions. These drugs were
developed as possible treatments for depression, some
forms of dementia, diabetes, and as add-on treatments
for Parkinson's disease and schizophrenia (Nutt and Pinder,
1996). A number of very selective molecules were made and
several were taken into human studies where clear evidence
of predicted pharmacological actions was found, e.g. in
sustaining attention (Coupland et al., 1994). Now none are
available for human study. Recently, as part of the ECNP
Medicines Chest initiative, we contacted GlaxoSmithKline
(GSK) in order to try to locate ﬂuparoxan, arguably the best
of these compounds. This was made in Glaxo in the 1980s
and has been used in humans (Johnson et al., 1995). Despite
the best efforts of senior members of the company the
records for ﬂuparoxan could not now be located in GSK. The
drug for all practical purposes is extinct. Currently we have
managed to make available another old α2 adrenoceptor
compound, idazoxan, in the Chest. This has a good safety
record in human studies (Glue et al., 1991) and clearly is-ND license.
Table 1 Target compounds for the ECNP medicines
chest initiative.
5-HT1A agonist Flesinoxan
5-HT1A antagonist Way100635
5-HT2A antagonist Volinanserin
(MDL100907)
5-HT2B antagonist RS127445
5-HT7 antagonist JNJ-18038683
Adrenergic α2 antagonist Fluparoxan
Cannabinoid CB1 antagonist Org 50189
Cannabinoid CB1 inverse agonist Rimonabant
Cannabinoid CB1/2 agonist Org 28611
Cannabinoid CB1/2 agonist Org 28312
Dopamine D1 agonist Adrogolide (ABT-431,
DAS-431)
Dopamine D1 antagonist ADX10061 (CEE 03-310;
NNC687)
Dopamine D3 antagonist GSK598809
Extrasynaptic GABA agonist Gaboxadol
Fatty acid amide hydrolase
(FAAH) antagonist
URB597, PF-622, PF-
750, PF-3845
GABAA α5 inverse agonist α5IA
GABAB antagonist CGP 35348
GABAα2/3 positive allosteric
modulator
L838417
Glycine transporter (GlyT-1)
inhibitor
Org 25935
Nicotinic α7 agonist JNJ-39393406,
GSK2182883
TSPO agonist Emapunil
http://www.ecnp.eu/projects-initiatives/ECNP-medici
nes-chest.aspx#.UooKTeDvn0A.
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1991). However idazoxan is not as selective as the com-
pounds mentioned above as it also binds to the imidazoline
I2 receptor.
You may say why not just make some more. That is of
course possible for preclinical research, though it would be
relatively expensive for a single researcher. However for
human studies under the Europe clinical trials directive this
would not sufﬁce. In order to give this drug to patients,
details of the exact drug substance and drug product
preparation used for the original compound are required.
Without this information from the company any researcher
would need to develop their own synthetic process, and
then re-do the animal and human toxicity testing before
being able to use the drug for research. This would cost
£k1000 or more, clearly outside any grant giving bodies'
budget. Moreover it is a waste of resource and animals.
Another example is that of the GABAA α5 subtype
receptor inverse agonist, α5IA, a compound made by Merck
Sharp & Dohme (MSD). This is the ﬁrst such compound to
have been shown to have the predicted pro-memory effects
in humans (Atack, 2010). Moreover in a mouse model of
Down's Syndrome, it normalised the memory deﬁcits in
several tasks (Braudeau et al., 2011). It was dropped by
MSD because it did not have a good enough memory
enhancing signal in studies of elderly volunteers with age-
related memory impairment. However when we tried to get
the information necessary to re-synthesise it for a proof-of-
concept trial in human patients with Down's Syndrome the
company was unable to make the necessary data available
and the costs of re-doing the full dossier were too large to
go for it alone.
2. The scale of the problem
The true extent of this loss of knowledge and compounds is
hard to ascertain as there is no systematic capture of this
kind of data. The ECNP has for some years been concerned
about it (Nutt and Goodwin, 2011) and approached the issue
from the perspective of its members through the Medicines
Chest initiative. We sent out a questionnaire to all our
members asking for compounds that they would like to
study but could not access. Over 50 were identiﬁed and then
those with the most requests were prioritised for further
exploration. Companies were approached to see if these
compounds had been discontinued or sold on, and in the
latter case we followed up with the new company. From this
process several important tool compounds with plausible
availability were identiﬁed – see Table 1. These cover a
range of biologically important receptors for which there
are in most cases no available alternatives.
3. How drugs disappear
It seems paradoxical that when so much is invested in
developing a compound it is allowed to die. Is it not a
resource on which further research can be done, leading to
new insights that can only be tested by the drug?
The reasons why drugs become extinct after failing in
clinical trials, or at least not made available for other
research, derive from a complex mixture of commercial andemotional decisions. Historically there might have been
active attempts to suppress knowledge of the “failure” of
a drug although this is becoming less of an issue now that
increasingly governments and regulators are requiring dis-
closure of all data from Phase 2 and Phase 3 trials,
irrespective of outcome. Additionally, some pharmaceutical
companies are run by individuals who may not see the value
of drug assets to the academic world.
There are also the costs involved in maintaining supplies
of the compounds for research. They need to be tested
for stability and purity on a regular basis and at some point
re-synthesised. Any subsequent work in patients will also
require some form of monitoring of adverse effects which
requires a data-base and someone to run it. All these have
tangible costs, which may deter companies. However, the
expenditures could be made more efﬁcient if a number of
groups are pulled together to work on one compound. An
intangible cost is the threat of litigation, particularly in the
US courts, should some harm come to a subject given the
drug. Although this is tenuous – why would a subject in say a
European study with local insurance sue the originating US
company? Some company lawyers will argue that there is a
minute chance of this happening, so it is better to play safe.
Such risk aversion tends to trump any pro-science arguments
that can be put forward. That said, most companies with
which we have discussed the Medicines Chest do not see this
as a major issue.
Table 2 Status of the Medicines Chest.
In the
chest
Gaboxadol (extra synaptic GABA agonist)
Idazoxan (α2 antagonist/imidazoline
antagonist)
Emapunil (TSPO agonist)
Probables 5-HT2A antagonist
GABAA alpha2/3 positive allosteric modulator
Histamine H3 inverse agonist
Dopamine D1 antagonist
CRF1 receptor antagonist
5-HT7 receptor antagonist
Nicotinic α7 receptor agonist
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The key to the success of this initiative is to make available
to bona ﬁde researchers with the necessary skills to
properly use them as many of these compounds as possible,
and to add more to the chest as time, money and compound
availability permits.
Targeted compounds for inclusion in the Medicines Chest
are those that have selective actions at important brain
targets which are currently inaccessible to academic
researchers for human studies. Such compounds will have
safety packages supporting use in humans. Preferably active
pharmaceutical ingredient will also be available but if not,
new material will need to be synthesised, the cost of which
will need to be met by funding bodies.
The ECNP Medicines Chest serves as a guardian of data for
compounds, maintains live Investigator's Brochures (and other
regulatory documentation) and where possible usable drug
substance and drug product. After agreement in principle that
a compound is available to the medicines chest, a template
agreement is established with the company. This or something
very similar is then used for each study, which are funded by
grant-giving bodies. The ECNP reviews study proposals to ensure
that only those of a high quality reach the company concerned.
Data generated from studies with compounds in the medicines
chest is made publically available.5. Gaboxadol – a successful example
Gaboxadol is already in the Chest. This is a Lundbeck
compound that was made to mimic the effects of the
natural inhibitory neurotransmitter GABA. As GABA is
involved in sleep regulation it was tested as a sleep
promoting drug where efﬁcacy was found but for various
reasons it was not taken to market. The neuroscience of
GABA receptors has evolved signiﬁcantly in the period
gaboxadol was under development and it now appears that
this drug is an extra-synaptic GABAA agonist working at a
speciﬁc subtype of this receptor class (Meera et al., 2011).
Gaboxadol is the only such compound currently known and
available for human work and so it is a critical tool for
exploring the role of these receptors in human brain
function. Through the Medicines Chest Lundbeck made it
possible to conduct a magnetoencephalography (MEG) study
with gaboxadol and compare it with other classes of drugs
that enhance GABAA function such as the intra-synaptic
agonist zolpidem and the GABA reuptake blocker tiagabine.
These results were remarkable as they, against all expecta-
tions, showed very different resting MEG proﬁles for the
three drugs, despite similar psychological effects. These
ﬁndings now need to be “back-translated” into preclinical
models of the role of GABA in cortical functioning.6. The current status of the Medicines Chest
Table 2 below shows the current status of the ECNP
Medicines Chest. Three compounds are in the chest and
discussions are ongoing for the “probables”; we hope to
have some of these in the chest in the next year.7. Conclusions
Clinical neuroscience lags behind its preclinical relative in
many ways, an important one being the lack of pharmacolo-
gical tools to study brain function. Many of these tool
compounds have been developed but almost none are avail-
able for human research. This situation is a serious indictment
of the current scientiﬁc process. Yet it is one that should be
avoidable given a willingness of the pharmaceutical industry to
make their assets available to researchers and the provision of
a mechanism for curating data and even test substances on
the drugs in question. The UK Medical Research Council (MRC)
and the Stanley Foundation have said that they will be pleased
to review grant proposals based on drugs from the Medicines
Chest, so what is now needed is a collective effort to make it
happen. The scale and cost of the initiative are too great for a
single organisation like ECNP to take on alone, though they are
happy to act as curators of the Medicines Chest. Possible other
sources of support include the new European Community
science initiative Horizons 2020 and the Innovative Medicines
Initiative (IMI) within it. Maybe the US and European human
brain projects will also consider supporting it?Role of funding source
ECNP provides a small amount of funding to support the medicines
chest initiative.Contributors
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